Developing the COVID-19 Vaccines with 2023 Nierenberg Prize Winner Katalin Karikó

Nobel Laureate and biochemist Katalin Karikó's groundbreaking work on COVID-19 vaccines earned her the Nobel Prize in Physiology or Medicine in 2023, alongside co-collaborator Drew Weissman. She's also the Scripps Institution of Oceanography's 2023 recipient of the Nierenberg Prize for Science in the Public Interest. Karikó, an adjunct professor of neurosurgery at the University of Pennsylvania, is best known for her research on messenger RNA - the genetic material that tells our bodies how to make proteins - and the development of mRNA COVID-19 vaccines. Karikó and Weissman invented the modified mRNA technology used in Pfizer-BioNTech and Moderna’s vaccines to prevent COVID-19 infection. In this program, Karikó talks about the progress and development of mRNA over the past six decades. Karikó will discuss the journey from the discovery of mRNA in 1961 to its groundbreaking milestone as the first FDA-approved mRNA product in the form of COVID-19 mRNA vaccines in 2021.
[7/2024] [Show ID: 39337]
Donate to UCTV to support informative & inspiring programming:
www.uctv.tv/do...
Please Note: Experts are working quickly to fight and respond to COVID-19. Knowledge about health and medicine is constantly evolving. This information may become out of date.
More videos from: Science in the Public Interest
(www.uctv.tv/ni...)
Explore More Health & Medicine on UCTV
(www.uctv.tv/he...)
UCTV features the latest in health and medicine from University of California medical schools. Find the information you need on cancer, transplantation, obesity, disease and much more.
UCTV is the broadcast and online media platform of the University of California, featuring programming from its ten campuses, three national labs and affiliated research institutions. UCTV explores a broad spectrum of subjects for a general audience, including science, health and medicine, public affairs, humanities, arts and music, business, education, and agriculture. Launched in January 2000, UCTV embraces the core missions of the University of California -- teaching, research, and public service - by providing quality, in-depth television far beyond the campus borders to inquisitive viewers around the world.
(www.uctv.tv)

[@Jaguarca23]

Wow you should be so proud

[@jasonphillip3755]

And bold too!

[@myparceltape1169]

After having to move around so much it must have been a difficult life.
Glad you saw some good results.

[@gmatheny8819]

What is the date of this seminar?

[@AnHonestDoubter]

What are the NNT and ADR numbers for C19 mRNA vaccines?

[@christopherrobinson7541]

ADR numbers less that for traditional vaccines.
NNT (or NNV) is dependent on the current prevence and the acquired immunity in the community; as more people become become infected they acquire more immunity and NNV falls. Also this metric depends on what is counted, ie; death, serious disease, hospitalization and infection etc.
Hence no simple answers.

[@AnHonestDoubter]

​@christopherrobinson7541 Where are you getting the data that ADR numbers for mRNA are less than traditional vaccines? As far as I've seen from adverse reporting data, there hasn't ever been a vaccine with more apparent ADR likelihood.
As for NNT for death, as these vaccines required (and still require) multiple boosters (4X+) and millions of administrations, the number must be very high (higher than a traditional univalent vaccine). Indeed, anyone who hasn't had a recent booster is virtually unprotected.
So yes, everything is obviously complex, yet it seems clear that the ADR and NNT numbers for mRNA delivery are concerning, especially when measured against one another for risk benefit analysis.

[@AnHonestDoubter]

​@@christopherrobinson7541data doesn't seem to bear out your claims, especially about ADR. And NNT must be very high considering the number of applications required.

[@AnHonestDoubter]

​@christopherrobinson7541 data doesn't seem to agree with your claims on ADR. NNT must also be quite high considering need for re-applications.

[@traianliviudanciu8665]

Did liposomes with mRNA transfect also vesel endothelial cells ?

[@Levihasherpez]

Sure, buddy.

[@mthor2346]

You're a lier!

[@traianliviudanciu8665]

What is the risk of blood spread of liposomes with mRNA ?
Did liposomes with mRNA transfect vesel endothelial cells ?

[@marcobsomer5574]

?????

[@user-nb4ex5zk3w]

Lots of laughter about this gene therapy experiment....good grief.